newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026

  • Ascentage Pharma presented Phase Ib study results for olverembatinib combined with blinatumomab in patients with lymphoid blast phase CML (CML-LBP) or Ph+ BCP-ALL at the 2026 ASCO Annual Meeting.
  • The combination regimen achieved a 91% complete response or complete response with incomplete hematologic recovery rate among 11 patients.
  • 67% of patients achieved BCR::ABL1 negativity by PCR, while 80% achieved minimal residual disease negativity by flow cytometry.
  • The safety profile of the combination was manageable, with most adverse events being grade 1-2 and consistent with known toxicities of the individual agents.
  • Olverembatinib is a third-generation BCR-ABL inhibitor currently approved in China for specific CML indications, including those with T315I mutations, and is covered by the China National Reimbursement Drug List.
  • The drug is jointly commercialized in China by Ascentage Pharma & Innovent Biologics, with an exclusive option agreement signed with Takeda for global rights outside China & certain regions.
  • Ascentage Pharma is conducting three global Phase III studies for olverembatinib in CML, newly diagnosed Ph+ ALL, & SDH-deficient GIST, with two cleared by the FDA & EMA.
  • This presentation marks the first validation of the olverembatinib & blinatumomab combination in international patients for these difficult-to-treat hematologic malignancies.